JP2010509226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509226A5 JP2010509226A5 JP2009535362A JP2009535362A JP2010509226A5 JP 2010509226 A5 JP2010509226 A5 JP 2010509226A5 JP 2009535362 A JP2009535362 A JP 2009535362A JP 2009535362 A JP2009535362 A JP 2009535362A JP 2010509226 A5 JP2010509226 A5 JP 2010509226A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- virus
- concentration
- present
- serum albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 164
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 33
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 33
- 241000700605 Viruses Species 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 29
- 241000710831 Flavivirus Species 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 235000013919 monopotassium glutamate Nutrition 0.000 claims description 15
- 238000007710 freezing Methods 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 12
- 230000002238 attenuated effect Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 8
- 208000001490 Dengue Diseases 0.000 claims description 8
- 206010012310 Dengue fever Diseases 0.000 claims description 8
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 8
- 241000700618 Vaccinia virus Species 0.000 claims description 8
- 241000710772 Yellow fever virus Species 0.000 claims description 8
- 239000004067 bulking agent Substances 0.000 claims description 8
- 208000025729 dengue disease Diseases 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 229940127557 pharmaceutical product Drugs 0.000 claims description 8
- 229940051021 yellow-fever virus Drugs 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 206010054261 Flavivirus infection Diseases 0.000 claims description 6
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 6
- 241000710886 West Nile virus Species 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 208000037384 Clostridium Infections Diseases 0.000 claims description 4
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 4
- 206010054236 Clostridium difficile infection Diseases 0.000 claims description 4
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 108010015780 Viral Core Proteins Proteins 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- -1 alkali metal glutamate Chemical class 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- 230000012743 protein tagging Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 3
- 102100034349 Integrase Human genes 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 101710188315 Protein X Proteins 0.000 claims description 3
- 101710172711 Structural protein Proteins 0.000 claims description 3
- 229940124965 ACAM2000 Drugs 0.000 claims description 2
- 241000707296 Alkhumra hemorrhagic fever virus Species 0.000 claims description 2
- 240000006108 Allium ampeloprasum Species 0.000 claims description 2
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000907515 Apoi virus Species 0.000 claims description 2
- 208000037404 Central European encephalitis Diseases 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241000609530 Ilheus virus Species 0.000 claims description 2
- 241000710912 Kunjin virus Species 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims description 2
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 2
- 241000538730 Rocio Species 0.000 claims description 2
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000009191 jumping Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims 2
- 241000907329 Russian Spring-Summer encephalitis virus Species 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85742406P | 2006-11-07 | 2006-11-07 | |
| US60/857,424 | 2006-11-07 | ||
| PCT/US2007/023421 WO2008057550A2 (en) | 2006-11-07 | 2007-11-07 | Stabilization of vaccines by lyophilization |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509226A JP2010509226A (ja) | 2010-03-25 |
| JP2010509226A5 true JP2010509226A5 (https=) | 2011-03-31 |
| JP5687836B2 JP5687836B2 (ja) | 2015-03-25 |
Family
ID=39365126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535362A Active JP5687836B2 (ja) | 2006-11-07 | 2007-11-07 | 凍結乾燥によるワクチンの安定化 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9132184B2 (https=) |
| EP (3) | EP2086581B1 (https=) |
| JP (1) | JP5687836B2 (https=) |
| CN (2) | CN106890144A (https=) |
| AR (1) | AR063606A1 (https=) |
| AU (1) | AU2007317847B2 (https=) |
| BR (1) | BRPI0718548A2 (https=) |
| CA (1) | CA2668834C (https=) |
| CL (1) | CL2007003209A1 (https=) |
| IL (1) | IL198563A0 (https=) |
| MX (1) | MX2009004862A (https=) |
| RU (1) | RU2541784C2 (https=) |
| TW (1) | TWI417113B (https=) |
| WO (1) | WO2008057550A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007003209A1 (es) | 2006-11-07 | 2008-05-09 | Acambis Inc | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion |
| HUE037932T2 (hu) | 2007-09-14 | 2018-09-28 | Sanofi Pasteur Biologics Llc | Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók |
| ES2615390T3 (es) | 2008-03-05 | 2017-06-06 | Sanofi Pasteur | Proceso para estabilizar una composición de vacuna que contiene adyuvante |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| US7998488B2 (en) * | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| SG175916A1 (en) * | 2009-04-08 | 2011-12-29 | Eu Yan Sang Internat Ltd | Uses of red yeast rice in treating dengue virus infection |
| CN102260351A (zh) * | 2010-05-25 | 2011-11-30 | 吉林圣元科技有限责任公司 | 流感病毒M2e蛋白的制备及其在抗甲型流感病毒中的应用 |
| AU2011336413B2 (en) * | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| DK2654784T3 (en) * | 2010-12-22 | 2017-02-13 | Wyeth Llc | STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES |
| SI2741740T1 (sl) * | 2011-08-12 | 2017-08-31 | Merial, Inc. | Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv |
| WO2013106398A1 (en) * | 2012-01-09 | 2013-07-18 | Sanofi Pasteur Biologics, Llc | Purification of herpes virus |
| WO2013177172A2 (en) | 2012-05-21 | 2013-11-28 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
| JP6426695B2 (ja) | 2013-03-14 | 2018-11-21 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 弱毒生アルファウイルス製剤のための組成物および方法 |
| WO2017056101A1 (en) | 2015-09-30 | 2017-04-06 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
| TWI766876B (zh) * | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
| RU2637634C1 (ru) * | 2016-10-21 | 2017-12-05 | Владимир Иосифович Лозинский | Антибактериальная белковая губка для химиотерапии инфицированных ран и способ ее получения |
| CN116421734A (zh) * | 2021-12-30 | 2023-07-14 | 深圳复诺健生物科技有限公司 | 适用于溶瘤病毒的冻干保护剂及其应用 |
| JPWO2024195868A1 (https=) * | 2023-03-23 | 2024-09-26 | ||
| WO2025027616A1 (en) * | 2023-08-01 | 2025-02-06 | Serum Institute Of India Private Limited | Freeze-dried viral vaccine compositions and method of manufacturing thereof |
| CN120173893B (zh) * | 2025-05-21 | 2025-08-12 | 宁波三生生物科技股份有限公司 | 一种锦鲤疱疹病毒的低温冻存保护液及其制备方法和应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337242A (en) * | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| JPS6013718A (ja) | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | Ｂ型肝炎ワクチン |
| US5173418A (en) | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| IE61575B1 (en) | 1987-05-04 | 1994-11-16 | Merck & Co Inc | A stable lyophilized live herpes virus vaccine |
| FR2633518B1 (fr) | 1988-06-30 | 1991-03-22 | Merieux Inst | Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues |
| US6676936B1 (en) | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| JPH09504429A (ja) | 1993-10-12 | 1997-05-06 | チロン ビアジーン，インコーポレイティド | 組換えウイルスの保存方法 |
| FR2719479B1 (fr) | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
| FR2740686B1 (fr) | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
| US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
| US6051238A (en) * | 1996-12-20 | 2000-04-18 | Merck & Co., Inc. | Stabilizers for lyophilized mumps vaccines |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| HU228705B1 (en) | 1997-02-28 | 2013-05-28 | Univ St Louis | Chimeric flavivirus vaccines |
| US20050096288A1 (en) * | 1997-06-13 | 2005-05-05 | Aragene, Inc. | Lipoproteins as nucleic acid vectors |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| ATE314476T1 (de) * | 1997-10-08 | 2006-01-15 | Us Gov Health & Human Serv | Chimärer impfstoff gegen das zeckenenzephalitis virus |
| CN1053590C (zh) * | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
| CN1062770C (zh) * | 1998-11-12 | 2001-03-07 | 卫生部长春生物制品研究所 | 甲肝-麻疹二联疫苗及其生产方法 |
| DE69940354D1 (de) | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
| EP2921180B1 (en) | 1999-02-22 | 2019-08-14 | University of Connecticut | Albumin-free factor VIII formulations |
| WO2001039802A1 (en) | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Chimeric flavivirus vaccines |
| US6589531B1 (en) | 2000-01-21 | 2003-07-08 | The Regents Of The University Of California | Recombinant yellow fever virus and method of use thereof |
| EP3000477A1 (en) * | 2000-02-16 | 2016-03-30 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Avirulent, immunogenic flavivirus chimeras |
| GB2372991B (en) | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
| US6723325B1 (en) * | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| WO2002102828A2 (en) | 2001-06-01 | 2002-12-27 | Acambis, Inc. | Chimeric flavivirus vectors |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| WO2003060088A2 (en) * | 2002-01-15 | 2003-07-24 | Acambis, Inc. | Viral vaccine production method |
| KR101194818B1 (ko) | 2002-01-15 | 2012-10-25 | 사노피 파스테르 바이오로직스, 엘엘씨 | 플라비바이러스 백신 |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| EP1471935A2 (de) | 2002-02-06 | 2004-11-03 | N-Zyme BioTec GmbH | Protease-screening und neue verwendung von proteasen |
| US7135180B2 (en) * | 2002-04-11 | 2006-11-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
| ATE452900T1 (de) | 2002-11-15 | 2010-01-15 | Sanofi Pasteur Biologics Co | Impfstoff gegen das west-nile-virus |
| US7588774B2 (en) * | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
| US7144712B2 (en) * | 2003-07-30 | 2006-12-05 | Vaccine Research Institute Of San Diego | Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| WO2005066333A1 (en) | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| EP1720519A1 (en) * | 2004-03-04 | 2006-11-15 | Wyeth | Lyophilization method to improve excipient crystallization |
| US7749520B2 (en) * | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| US20060167022A1 (en) * | 2004-09-08 | 2006-07-27 | Woodward John R | Method of female sexual enhancement |
| JP4993301B2 (ja) | 2004-10-20 | 2012-08-08 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
| US20060121055A1 (en) * | 2004-12-06 | 2006-06-08 | Becton, Dickinson And Company, Inc. | Compositions with enhanced immunogenicity |
| CN101090966B (zh) | 2004-12-24 | 2012-07-04 | 财团法人阪大微生物病研究会 | 具有减毒日本脑炎病毒基因作为主链的减毒嵌合黄病毒 |
| CA2605924A1 (en) | 2005-04-24 | 2006-11-02 | Acambis Inc. | Recombinant flavivirus vaccines |
| CL2007003209A1 (es) | 2006-11-07 | 2008-05-09 | Acambis Inc | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion |
-
2007
- 2007-11-07 CL CL2007003209A patent/CL2007003209A1/es unknown
- 2007-11-07 BR BRPI0718548 patent/BRPI0718548A2/pt not_active IP Right Cessation
- 2007-11-07 EP EP20070861777 patent/EP2086581B1/en active Active
- 2007-11-07 US US12/513,935 patent/US9132184B2/en active Active
- 2007-11-07 EP EP20120177150 patent/EP2535058A3/en not_active Withdrawn
- 2007-11-07 CN CN201710026145.2A patent/CN106890144A/zh active Pending
- 2007-11-07 CN CN200780049359A patent/CN101808657A/zh active Pending
- 2007-11-07 CA CA2668834A patent/CA2668834C/en active Active
- 2007-11-07 JP JP2009535362A patent/JP5687836B2/ja active Active
- 2007-11-07 TW TW96141996A patent/TWI417113B/zh active
- 2007-11-07 EP EP14180710.7A patent/EP2851087B2/en active Active
- 2007-11-07 AR ARP070104963 patent/AR063606A1/es not_active Application Discontinuation
- 2007-11-07 MX MX2009004862A patent/MX2009004862A/es not_active Application Discontinuation
- 2007-11-07 AU AU2007317847A patent/AU2007317847B2/en active Active
- 2007-11-07 WO PCT/US2007/023421 patent/WO2008057550A2/en not_active Ceased
- 2007-11-07 RU RU2009121566/10A patent/RU2541784C2/ru not_active Application Discontinuation
-
2009
- 2009-05-05 IL IL198563A patent/IL198563A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509226A5 (https=) | ||
| RU2009121566A (ru) | Стабилизация вакцин лиофилизацией | |
| CN111655844B (zh) | 包含特别是减毒活重组黄病毒的稳定的疫苗组合物及其制备方法 | |
| CN1263508C (zh) | 活疫苗的稳定剂 | |
| EP2143440A1 (fr) | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués | |
| HK1217168A1 (zh) | 用於活的减毒病毒的方法和组合物 | |
| JP2019532949A (ja) | 耐熱保護剤、室温で保存可能な豚コレラ生ワクチンの製造方法及びその使用 | |
| KR20180041761A (ko) | 안정한 약독화된 재조합 뎅기 생백신 | |
| KR102544928B1 (ko) | 아미노산을 유효성분으로 함유하는 동물용 백신 또는 진단용 항원의 안정성 증진용 조성물 및 이의 용도 | |
| CN107531747A (zh) | 蛋白质的稳定 | |
| AU2019362276A1 (en) | Virus vaccine |